![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
Details:
SP-002 is a biologic therapeutic based on an adenovirus, that has been engineered to produce the immunostimulatory anti-cancer protein, Interferon-g. It is being investigated in combination with vismodegib for treating locally advanced and metastatic basal cell carcinoma.
Lead Product(s): SP-002,Vismodegib
Therapeutic Area: Oncology Product Name: SP-002
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024